Systematic integration of biomedical knowledge prioritizes drugs for repurposing

@article{Himmelstein2017SystematicIO,
  title={Systematic integration of biomedical knowledge prioritizes drugs for repurposing},
  author={Daniel S. Himmelstein and Antoine Lizee and Christine Hessler and Leo Brueggeman and Sabrina L Chen and Dexter Hadley and Ari J. Green and Pouya Khankhanian and Sergio E. Baranzini},
  journal={eLife},
  year={2017},
  volume={6}
}
The ability to computationally predict whether a compound treats a disease would improve the economy and success rate of drug approval. This study describes Project Rephetio to systematically model drug efficacy based on 755 existing treatments. First, we constructed Hetionet (neo4j.het.io), an integrative network encoding knowledge from millions of biomedical studies. Hetionet v1.0 consists of 47,031 nodes of 11 types and 2,250,197 relationships of 24 types. Data was integrated from 29 public… 

Figures and Tables from this paper

Overcoming sparseness of biomedical networks to identify drug repositioning candidates
TLDR
This work presents a computational method for inferring drug-disease associations from complex but incomplete and biased biological networks, employing the compressed sensing technique to overcome the sparseness of biomedical data and to enrich the set of verified relationships between different biomedical entities.
Disease networks and their contribution to disease understanding and drug repurposing. A survey of the state of the art
TLDR
The evolution of disease network concept during the last decade is analyzed and a data science pipeline approach is applied to evaluate their functional units to obtain a list of the most commonly used functional units and the challenges that remain to be solved.
Leveraging Distributed Biomedical Knowledge Sources to Discover Novel Uses for Known Drugs
TLDR
This study uses a graph-based approach to integrate biological knowledge from 20 publicly accessible repositories to represent information involving 11 distinct bioentity types and uses a random forest model to make novel predictions about which drugs can be used to treat certain diseases.
Building a Knowledge Graph to Enable Precision Medicine
TLDR
PrimeKG is presented, a precision medicine-oriented knowledge graph that provides a holistic view of diseases and supports artificial intelligence analyses of how drugs might target disease-associated molecular perturbations by containing an abundance of ‘indications’, ‘contradictions’ and ‘off-label use’ drug-disease edges lacking in other knowledge graphs.
Machine learning identifies candidates for drug repurposing in Alzheimer's disease.
TLDR
DRIAD (Drug Repurposing In AD), a machine learning framework that quantifies potential associations between the pathology of AD severity (the Braak stage) and molecular mechanisms as encoded in lists of gene names, is presented.
Machine Learning Identifies Novel Candidates for Drug Repurposing in Alzheimer’s Disease
TLDR
It is proposed that the DRIAD method can be used to nominate drugs that, after additional validation and identification of relevant pharmacodynamic biomarker(s), could be evaluated in a clinical trial.
Drug prioritization using the semantic properties of a knowledge graph
TLDR
The semantic properties of concepts in a knowledge graph can be exploited to prioritize drug repurposing candidates for testing in clinical trials, and this work uses the semantic information between drug and disease concepts as features from an existing knowledge graph that integrates 200 different biological knowledge sources.
A Network Medicine Approach to Drug Repurposing for Chronic Pancreatitis
Despite decades of clinical investigations, there is currently no effective treatment for patients diagnosed with Chronic Pancreatitis (CP). Computational drug repurposing holds promise to rapidly
A Network Polypharmacological Approach to Combinatorial Drug Repurposing for Diffuse Intrinsic Pontine Glioma
TLDR
It is proposed that by using a polypharmacological approach to determine drug combinations that target distinct mechanistic pathways of DIPG, it is more likely that an efficacious treatment will be developed.
MGATRx: Discovering Drug Repositioning Candidates Using Multi-view Graph Attention
TLDR
This work proposes a multi-view graph attention network for indication discovery (MGATRx), which outperformed four other state-of-art methods used for computational drug repositioning and predicted novel indications are either currently investigated or are supported by literature evidence, demonstrating the overall translational utility of MGATRX.
...
...

References

SHOWING 1-10 OF 368 REFERENCES
In silico methods for drug repurposing and pharmacology
TLDR
It is argued that methods such as matrix factorization that can integrate data within and across diverse data types have the potential to improve predictive performance and provide a fuller picture of a drug's pharmacological action.
Network-based in silico drug efficacy screening
TLDR
This work introduces a drug-disease proximity measure that quantifies the interplay between drugs targets and diseases, and indicates that the therapeutic effect of drugs is localized in a small network neighborhood of the disease genes.
Systematic evaluation of connectivity map for disease indications
TLDR
Three CMAP-based methods are evaluated on their prediction performance against a curated dataset of 890 true drug-indication pairs to demonstrate the power of connectivity map in classifying known drug-disease relationships.
Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning
TLDR
RepurposeDB is developed as the reference database for drug repositioning investigations, a collection of repurposed drugs, drug targets and diseases which was assembled, indexed and annotated from public data to address knowledge and clinical needs.
Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data
TLDR
A systematic computational approach to predict novel therapeutic indications on the basis of comprehensive testing of molecular signatures in drug-disease pairs for repositioning established drugs to treat a wide range of human diseases.
LabeledIn: Cataloging labeled indications for human drugs
Pathway-based Bayesian inference of drug-disease interactions.
TLDR
This work developed a Bayesian matrix factorisation of gene expression data together with known gene-pathway memberships and implemented a Gaussian Markov Random Field (GMRF) under the matrix factorization framework to identify pathways perturbed by drugs.
PREDICT: a method for inferring novel drug indications with application to personalized medicine
TLDR
A novel method for the large‐scale prediction of drug indications (PREDICT) that can handle both approved drugs and novel molecules and lays the computational foundation for future personalized drug treatments, where gene expression signatures from individual patients would replace the disease‐specific signatures.
Computational Drug Repositioning: From Data to Therapeutics
TLDR
Computational techniques for systematic analysis of transcriptomics, side effects, and genetics data to generate new hypotheses for additional indications and data domains such as electronic health records (EHRs) and phenotypic screening that are considered promising for novel computational repositioning methods are discussed.
DrugBank 4.0: shedding new light on drug metabolism
TLDR
The latest update of DrugBank, DrugBank 4.0, has been further expanded to contain data on drug metabolism, absorption, distribution, metabolism, excretion and toxicity (ADMET) and other kinds of quantitative structure activity relationships (QSAR) information.
...
...